Orchestra BioMed Holdings, Inc. (OBIO)

NGM – Real Time Price. Currency in USD

4.06

0.00 (0.00%)

At close: May 13, 2026, 4:00 PM EDT

4.06

0.00 (0.00%)

After-hours: May 13, 2026, 4:10 PM EDT

12.05.2026

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.49 per share a year ago.

12.05.2026

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

NEW HOPE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2026, and provided a business update highlighting momentum across the Company's pivotal-stage programs for Atrioventricular Interval Modulation (“AVIM”) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue SAB”) supported by the Company's strong balance sheet.

12.05.2026

Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027

NEW HOPE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced an update to the overall clinical and regulatory timeline for the BACKBEAT Trial evaluating Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) in pacemaker-indicated patients with uncontrolled hypertension despite medications. The Company is targeting completion of enrollment by the end of the third quarter of 2026. Further, the Company and Medtronic, its strategic collaborator for the BACKBEAT Trial and the commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in patients indicated for a pacemaker, plan to submit the primary endpoint data for a late-breaking clinical trial presentation at a major cardiovascular conference in the second quarter of 2027. Lastly, assuming primary safety and efficacy endpoints are met, Medtronic plans to submit a marketing application for FDA approval after primary endpoint data analyses and reports are complete, and subsequently to pursue global regulatory approvals.

06.05.2026

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of a $15 million payment from Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) pursuant to the previously disclosed Revenue Participation Right Purchase and Sale Agreement (the “Royalty Purchase Agreement”). The payment completes a scheduled tranche under the agreement and reflects Ligand's continued strategic capital support of Orchestra BioMed's late-stage cardiovascular programs, AVIM Therapy and Virtue SAB, which are both being evaluated in ongoing randomized, controlled pivotal trials.

06.05.2026

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) evaluating Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) in patients with uncontrolled hypertension and an indication for a pacemaker as part of the strategic collaboration between Orchestra BioMed and Medtronic This payment, together with $15 million received from Ligand and announced separately, represents a total of $35 million in strategic capital received under previously disclosed agreements NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of a $20 million investment from Medtronic, plc.

30.04.2026

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Atrioventricular Interval Modulation (“AVIM”) Therapy Food and Drug Administration (“FDA”) Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension despite medication at increased cardiovascular risk and the specific pacemaker-indicated population being evaluated in the BACKBEAT Trial The addressable U.S. patient population for AVIM Therapy, based on the indications for use specified in its Breakthrough Device Designations, comprises over 7.7 million adults with hypertension despite medication Breakthrough Device Designation supports favorable reimbursement pathways, including potential eligibility for New Technology Add-on Payment (“NTAP”) and Transitional Pass-Through (“TPT”) payment, which can facilitate broader, more timely patient access and provider adoption NEW HOPE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that the FDA has granted a second Breakthrough Device Designation (“BDD”) for AVIM Therapy specific to patients with uncontrolled hypertension despite the use of anti-hypertensive medications, and an indication for a pacemaker.

23.04.2026

Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

NEW HOPE, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced two AVIM Therapy presentations at the Heart Rhythm Society (HRS) 2026 Annual Meeting.

Videos

No Data

There is no data to display

Press releases

12.05.2026

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

12.05.2026

Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027

06.05.2026

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

06.05.2026

Orchestra BioMed Holdings, Inc. (OBIO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Orchestra BioMed Holdings, Inc. (OBIO)

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

Videos

No Data

Press releases

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

Videos

No Data

Press releases

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

Search stocks

Orchestra BioMed Holdings, Inc. (OBIO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Orchestra BioMed Holdings, Inc. (OBIO)

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

Videos

No Data

Press releases

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

Videos

No Data

Press releases

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement